283 related articles for article (PubMed ID: 32296574)
1. COX-2 as a potential biomarker and therapeutic target in melanoma.
Tudor DV; Bâldea I; Lupu M; Kacso T; Kutasi E; Hopârtean A; Stretea R; Gabriela Filip A
Cancer Biol Med; 2020 Feb; 17(1):20-31. PubMed ID: 32296574
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Gowda R; Sharma A; Robertson GP
Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
[TBL] [Abstract][Full Text] [Related]
3. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
[TBL] [Abstract][Full Text] [Related]
4. Does the gastrointestinal microbiome contribute to the 'obesity paradox' in melanoma survival?
Langan EA; Grätz V; Billmann F; Zillikens D; Terheyden P
Br J Dermatol; 2018 Jul; 179(1):225-226. PubMed ID: 29663324
[No Abstract] [Full Text] [Related]
5. Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.
Tudor DV; Bâldea I; Olteanu DE; Fischer-Fodor E; Piroska V; Lupu M; Călinici T; Decea RM; Filip GA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922284
[TBL] [Abstract][Full Text] [Related]
6. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
Gulyas M; Mattsson JSM; Lindgren A; Ek L; Lamberg Lundström K; Behndig A; Holmberg E; Micke P; Bergman B;
Acta Oncol; 2018 Feb; 57(2):244-250. PubMed ID: 29140138
[TBL] [Abstract][Full Text] [Related]
7. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
8. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
9. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
10. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
Durgin JS; Weiner DM; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
[TBL] [Abstract][Full Text] [Related]
11. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol-β-glucan Inhibits Melanoma Growth via Interacting with Dectin-1 to Polarize Macrophages into M1 Phenotype.
Liu X; Xu Y; Li Y; Pan Y; Zhao S; Hou Y
Int J Med Sci; 2021; 18(14):3125-3139. PubMed ID: 34400883
[No Abstract] [Full Text] [Related]
13. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
15. Research progress in advanced melanoma.
Luo C; Shen J
Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
[TBL] [Abstract][Full Text] [Related]
16. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
Wang Z; Peng M
Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
[TBL] [Abstract][Full Text] [Related]
18. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
Rozeman EA; Dekker TJA; Haanen JBAG; Blank CU
Am J Clin Dermatol; 2018 Jun; 19(3):303-317. PubMed ID: 29164492
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
20. Heme catabolism by tumor-associated macrophages controls metastasis formation.
Consonni FM; Bleve A; Totaro MG; Storto M; Kunderfranco P; Termanini A; Pasqualini F; Alì C; Pandolfo C; Sgambelluri F; Grazia G; Santinami M; Maurichi A; Milione M; Erreni M; Doni A; Fabbri M; Gribaldo L; Rulli E; Soares MP; Torri V; Mortarini R; Anichini A; Sica A
Nat Immunol; 2021 May; 22(5):595-606. PubMed ID: 33903766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
